메뉴 건너뛰기




Volumn 4, Issue 6, 2004, Pages 617-624

The second generation of COX-2 inhibitors: Clinical pharmacological point of view

Author keywords

Efficacy; Etoricoxib; Inflammation; Lumiracoxib; Pain; Parecoxib; Safety; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CS 502; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIGOXIN; ETORICOXIB; FENTANYL; GLIBENCLAMIDE; GLUCOCORTICOID; IBUPROFEN; KETOROLAC; LUMIRACOXIB; METHOTREXATE; MIDAZOLAM; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PARACETAMOL; PARECOXIB; PREDNISOLONE; PROPOFOL; RIFAMPICIN; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

EID: 3242720430     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557043403783     Document Type: Short Survey
Times cited : (12)

References (68)
  • 1
  • 46
    • 3242673142 scopus 로고    scopus 로고
    • Product information Bextra®. Pharmacia Europe EEIG, High Wycombe, Great Britain, March
    • Product information Bextra®. Pharmacia Europe EEIG, High Wycombe, Great Britain, March, 2003.
    • (2003)
  • 47
    • 3242715639 scopus 로고    scopus 로고
    • Product information Dynastat®. Pharmacia Europe EEIG, High Wycombe, Great Britain, March
    • Product information Dynastat®. Pharmacia Europe EEIG, High Wycombe, Great Britain, March, 2003.
    • (2003)
  • 54
    • 85039497461 scopus 로고    scopus 로고
    • Product Information Bextra®. Searle, Pharmacia Corporation, Chicago, IL, October
    • Product Information Bextra®. Searle, Pharmacia Corporation, Chicago, IL, October, 2003.
    • (2003)
  • 55
    • 85039497366 scopus 로고    scopus 로고
    • FDA-Review NDA 21-341. www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm. May 30
    • FDA-Review NDA 21-341. www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm. May 30, 2002.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.